Haemoglobin A1c--a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS).
about
Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood HbA(1c) in obese type 2 diabetes patientsLong chain polyunsaturated fatty acids (LCPUFAs) and nordihydroguaiaretic acid (NDGA) modulate metabolic and inflammatory markers in a spontaneous type 2 diabetes mellitus model (Stillman Salgado rats)Accuracy and robustness of dynamical tracking of average glycemia (A1c) to provide real-time estimation of hemoglobin A1c using routine self-monitored blood glucose dataScreening for diabetes in Indigenous populations using glycated haemoglobin: sensitivity, specificity, post-test likelihood and risk of disease.Using hemoglobin A1C as a predicting model for time interval from pre-diabetes progressing to diabetes.Diabetic retinopathy in patients with newly diagnosed type 2 diabetes mellitus in Jordan: prevalence and associated factors.Obesity, glucose intolerance and diabetes and their links to cardiovascular disease. Implications for laboratory medicine.HbA1c, fasting and 2 h plasma glucose in current, ex- and never-smokers: a meta-analysis.Reliability and validity of diabetes specific Health Beliefs Model scales in patients with diabetes and serious mental illnessAnalysis and Quantitation of Glycated Hemoglobin by Matrix Assisted Laser Desorption/Ionization Time of Flight Mass Spectrometry.Prolonged exercise training increases intramuscular lipid content and perilipin 2 expression in type I muscle fibers of patients with type 2 diabetes.Are we measuring what matters in health technology assessment of disease management? Systematic literature review.Evaluation of a Methodology for Estimating HbA1c Value by a New Glucose Meter.Physical activity in obesity and metabolic syndromeBimodal distribution of glucose is not universally useful for diagnosing diabetesControlled-release carvedilol in the management of systemic hypertension and myocardial dysfunctionLong-term complications and mortality in young-onset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes.Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.Telemedicine-based KADIS combined with CGMS has high potential for improving outpatient diabetes care.Hierarchical Bayesian Logistic Regression to forecast metabolic control in type 2 DM patients.Strength training as a countermeasure to aging muscle and chronic disease.Proteomics as a tool to discover biomarkers for the prediction of diabetic complications.Intensification of medication and glycaemic control among patients with type 2 diabetes - the ADVANCE trial.Current concepts of pharmacotherapy in hypertension. Carvedilol: new considerations for its use in the diabetic patient with hypertension.Interpretation of HbA1c : association with mean cell volume and haemoglobin concentration.Cardiovascular Mortality of Oral Antidiabetic Drugs Approved Before and After the 2008 US FDA Guidance for Industry: A Systemic Review and Meta-Analysis.Interaction of herbal compounds with biological targets: a case study with berberine.Continuous endurance-type exercise training does not modulate satellite cell content in obese type 2 diabetes patientsThe Pathobiology of Diabetes Mellitus
P2860
Q28241481-7A1BFBD6-A09B-4494-BE0C-4CEF3213D2A6Q28593139-98923BEE-211B-4017-85CF-59ED24EABF7CQ30457190-DD93F4F5-2402-411B-824B-3B69D17D2697Q33217754-18E98400-F0D3-438D-97F8-C6D77798E6CCQ34004933-DE40B8B3-A9CB-4404-B79C-D343DB7848C8Q34481189-95131F13-167F-4DF5-B651-4BE3EC87C95DQ34543079-D8C992F1-75BA-427D-91EE-3E40188E461FQ34559044-D2782C66-0016-436D-B766-39B7F0C50F10Q35032651-8DF38FF2-0641-412F-855F-D9299168EB78Q35886251-99E9F052-8C68-47D7-BA9D-61160011435EQ36382538-6CD4B56F-E29C-41A2-86F5-419D21F3AC4EQ36468096-1E8DBD97-53A6-4D6F-BEB4-635EB17EDF7FQ36535904-9493155E-D625-4515-9A54-85DF84013182Q37023893-2D70ACFC-D906-4D9F-8635-A12A179BDC5AQ37105153-0350C57A-2604-4E50-8B02-A1BBA4FB4750Q37145670-2DC0CFBB-DC6C-4B27-B15E-BA608021E2BAQ37331122-036D651C-A62F-489F-93E0-843EDAB7701FQ37346130-662DFFF3-BE55-4A57-B26E-BA7596413CADQ37403953-FA030362-B32D-41CE-82D5-3BDF4FA9AC43Q37676569-95D9ADD0-6F79-4FC7-9604-2C6C56371711Q37855784-9D8DE17B-531B-4887-B82B-F47A3D966882Q38089733-57636947-713A-4D58-8D23-44B43E2CF208Q44004103-BD14676F-10D7-425B-80D0-DC5C9AFFC51EQ44907719-BE1060AB-B8F8-4126-A2C4-B0C712F7FB9FQ51321182-57BCA11D-8537-44D5-B2A6-E4DABAF25E77Q51736764-F190A6C9-4915-471B-9A93-DFE5F999B342Q53130900-73C787F6-2908-4AF8-9EDB-5BFBFCBBF47DQ57580366-D61682B9-5A52-4F27-BAAA-422F6DFD9671Q58316252-451D7E3D-0A53-4985-8533-81C1BF625417
P2860
Haemoglobin A1c--a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS).
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@ast
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@en
type
label
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@ast
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@en
prefLabel
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@ast
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@en
P2860
P356
P1476
Haemoglobin A1c--a marker for ...... ective Diabetes Study (UKPDS).
@en
P2093
Susan Manley
P2860
P304
P356
10.1515/CCLM.2003.182
P577
2003-09-01T00:00:00Z